Form 4: United Therapeutics EVP Exercises Share Tracking Awards Under 10b5-1 Plan
SEC Form 4
Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.
Summary
- Paul A. Mahon, the EVP & General Counsel of United Therapeutics Corporation, executed a transaction involving share tracking awards on January 2, 2025.
- The transaction involved the exercise of 7,700 share tracking awards at a price of $163.3 per share.
- This exercise was conducted under a pre-arranged 10b5-1 plan established on June 20, 2024.
- Following the transaction, Mahon directly owns 36,710 shares of common stock and 29,650 share tracking awards.
- Share tracking awards are non-dilutive cash-settled stock appreciation rights that can only be settled in cash and are not convertible into common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports a routine transaction under a pre-existing plan. There is no indication of positive or negative implications for the company.
Positives
- The transaction was executed under a pre-arranged 10b5-1 plan, indicating a planned and compliant approach to trading.
- The executive still holds a significant number of common stock shares (36,710) and share tracking awards (29,650) after the transaction, indicating continued alignment with the company's performance.
Industry Context
Executive compensation and trading activity are closely monitored in the pharmaceutical industry to ensure compliance and alignment of interests. Transactions under 10b5-1 plans are common and provide a structured approach to insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options, restricted stock units (RSUs), and stock appreciation rights (SARs) to incentivize performance and align executive interests with shareholder value.
- The use of 10b5-1 plans is a standard practice among corporate executives to manage potential insider trading concerns when selling company stock.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar compensation structures and trading plans for their executives.
Stakeholder Impact
- The transaction itself is unlikely to have a significant impact on stakeholders, as it is a planned execution of existing compensation arrangements.
- Shareholders may view the transaction as a routine part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/13/2016 | Date exercisable for Share Tracking Award |
| 06/20/2024 | Date of pre-arranged 10b5-1 plan entered into by the reporting person |
| 01/02/2025 | Date of transaction (exercise of share tracking awards) |
| 01/03/2025 | Date of signature |
| 03/13/2025 | Expiration Date for Share Tracking Award |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.